DOT1L INHIBITORS AND USES THEREOF
The present disclosure relates to methods of treating AML associated with DNMT3A mutations by administering one or more DOT1L inhibitors or related pharmaceutical compositions to subjects in need thereof
1 . A method of treating acute myeloid leukemia (AML), the method comprising administering a composition comprising a DOT1L inhibitor to a subject having AML associated with one or more DNMT3A mutations.
2 . The method of claim 1 , wherein the one or more DNMT3A mutations cause a dominant negative loss of function of DNMT3A activity.
3 . The method of claim 1 , wherein a biological sample from the subject is identified as having one or more expanded DNA methylation canyons.
4 . The method of claim 3 , wherein the one or more expanded DNA methylation canyons comprise a HOX gene cluster.
5 . The method of claim 4 , wherein the HOX gene cluster is a HOXA gene cluster.
6 . The method of claim 4 , wherein the HOX gene cluster is a HOXB gene cluster.
7 . The method of claim 1 , wherein a biological sample from the subject is identified as having a level of H3K79me2 that is higher than in a DNMT3A wild-type control.
8 . A method of treating a subject having AML, the method comprising:
a. obtaining a biological sample from the subject;
b. detecting the presence of one or more DNMT3A mutations in the biological sample, detecting the presence of one or more expanded DNA methylation canyons in the biological sample, or detecting the presence of a higher level of H3K79me2 in the biological sample than in a DNMT3A wild-type control; and,
c. administering to the subject a composition comprising a DOT1L inhibitor.
9 .- 10 . (canceled)
11 . A method of identifying a subject having AML that is responsive to treatment with a DOT1L inhibitor, the method comprising:
a. obtaining a biological sample from the subject;
b. assaying the biological sample for the presence of one or more DNMT3A mutations, assaying the biological sample for the presence of one or more expanded DNA methylation canyons, or assaying a level of H3K79me2 in the biological sample; and,
c. identifying the subject as responsive to treatment with a DOT1L inhibitor if one or more DNMT3A mutations are detected in the biological sample, if one or more expanded DNA methylation canyons are detected in the biological sample, or if the level of H3K79me2 is higher than in a DNMT3A wild-type control.
12 .- 13 . (canceled)
14 . The method of claim 1 , wherein the DOT1L inhibitor is a compound of formula:
or a pharmaceutically acceptable salt thereof.
15 . The method of claim 1 , wherein the DOT1L inhibitor is a compound of formula:
wherein R1 is a H, or a pharmaceutically acceptable salt thereof.
16 . The method of claim 1 , wherein the DOT1L inhibitor is a compound of formula:
or a pharmaceutically acceptable salt thereof.
17 . The method of claim 8 , wherein the biological sample is selected from the group consisting of bone marrow, peripheral blood cells, blood, cerebrospinal fluid, skin lesions, chloroma biopsy, plasma, serum, urine, saliva and a cell.
18 . The method of claim 1 , wherein the presence of one or more mutations of DNMT3A are detected by genome sequence analysis, next generation sequencing, and/or PCR-based mutation detection.